LGVN Longeveron

Longeveron Inc. to Present at the Q1 Virtual Investor Summit on March 24

Longeveron Inc. to Present at the Q1 Virtual Investor Summit on March 24

MIAMI, March 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that Geoff Green, CEO of Longeveron, will be presenting at the Q1 Virtual Investor Summit.



EventQ1 Investor Summit
DateMarch 23-25, 2021
PresentationMarch 24 @ 10:00 am ET
Location



About The Investor Summit

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q1 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors. 



To request complimentary investor registration: please visit our website at

About Longeveron

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Additional information about the Company is available at .

Contact:

Crescendo Communications, LLC

Tel: 212-671-1020

Email:

Investor Summit Contact: 

Brittney Blocker at

Wire Service Contact

InvestorWire (IW)

Los Angeles, California



212.418.1217 Office



EN
19/03/2021

Underlying

LGVNLongeveron

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Longeveron

 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Announces 2025 Full Year Financial Results and Provides Bus...

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Co...

March 17, 2026 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron to Report 2025 Full-Year Financial Results and Host Confere...

Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026 MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2025 full year financial results and provide a business update on Tuesday, March 17, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference ...

March 12, 2026 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Announces Closing of Private Placement of up to $30 Million

Longeveron Announces Closing of Private Placement of up to $30 Million $15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules Private placement led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsInitial proceeds extend cash runway into 4Q26, past the anticipated pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout MIAMI, March 11, 2026 (GLOBE NEWSWIRE) --...

March 11, 2026 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Announces Private Placement of up to $30 Million

Longeveron Announces Private Placement of up to $30 Million $15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules Private placement led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsInitial proceeds extend cash runway into 4Q26, past the anticipated pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- Longeveron...

March 10, 2026 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell...

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic aging-related conditions, today announced that results of its Phase 2b clinical trial were published today in , a Cell Press Journal. The Phase 2b results demonstrated that intravenous laromestrocel, a mesenchymal stem cell product, improved the phys...

February 25, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch